Pavel I. Pilipenko, Anna A. Ivanova, Yulia V. Kotsiubinskaya, Vera N. Grigoryeva, Alexey Y. Khrulev, Anatoly V. Skorokhodov, Maxim M. Gavrik, Nona N. Mkrtchan, Marek Majdan, Peter Valkovic, Daria Babarova, Suzanne Barker-Collo, Kelly Jones, Valery L. Feigin
{"title":"MLC901(neuroaid II™)治疗轻度脑外伤后认知障碍的双盲、安慰剂对照、随机、多中心、III 期研究","authors":"Pavel I. Pilipenko, Anna A. Ivanova, Yulia V. Kotsiubinskaya, Vera N. Grigoryeva, Alexey Y. Khrulev, Anatoly V. Skorokhodov, Maxim M. Gavrik, Nona N. Mkrtchan, Marek Majdan, Peter Valkovic, Daria Babarova, Suzanne Barker-Collo, Kelly Jones, Valery L. Feigin","doi":"10.1101/2024.08.28.24312757","DOIUrl":null,"url":null,"abstract":"<strong>Introduction</strong> About half of the world population will suffer from a traumatic brain injury (TBI) during their lifetime, of which about 90% of cases are mild TBI. About 15-40% of adults with TBI experience persistent cognitive deficits, and there is a lack of proven-effective treatment to facilitate cognitive recovery after mild TBI.","PeriodicalId":501367,"journal":{"name":"medRxiv - Neurology","volume":"202 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTI-CENTRE, PHASE III STUDY OF MLC901 (NEUROAID II™) FOR THE TREATMENT OF COGNITIVE IMPAIRMENT AFTER MILD TRAUMATIC BRAIN INJURY\",\"authors\":\"Pavel I. Pilipenko, Anna A. Ivanova, Yulia V. Kotsiubinskaya, Vera N. Grigoryeva, Alexey Y. Khrulev, Anatoly V. Skorokhodov, Maxim M. Gavrik, Nona N. Mkrtchan, Marek Majdan, Peter Valkovic, Daria Babarova, Suzanne Barker-Collo, Kelly Jones, Valery L. Feigin\",\"doi\":\"10.1101/2024.08.28.24312757\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<strong>Introduction</strong> About half of the world population will suffer from a traumatic brain injury (TBI) during their lifetime, of which about 90% of cases are mild TBI. About 15-40% of adults with TBI experience persistent cognitive deficits, and there is a lack of proven-effective treatment to facilitate cognitive recovery after mild TBI.\",\"PeriodicalId\":501367,\"journal\":{\"name\":\"medRxiv - Neurology\",\"volume\":\"202 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Neurology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.08.28.24312757\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.08.28.24312757","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTI-CENTRE, PHASE III STUDY OF MLC901 (NEUROAID II™) FOR THE TREATMENT OF COGNITIVE IMPAIRMENT AFTER MILD TRAUMATIC BRAIN INJURY
Introduction About half of the world population will suffer from a traumatic brain injury (TBI) during their lifetime, of which about 90% of cases are mild TBI. About 15-40% of adults with TBI experience persistent cognitive deficits, and there is a lack of proven-effective treatment to facilitate cognitive recovery after mild TBI.